BME:GRFBiotechs
Grifols Revenue Growth And Fibrinogen Launch Shape Evolving Investment Story
Grifols reported a solid revenue increase in 2025.
The company improved free cash flow during the year.
Grifols launched a new fibrinogen concentrate in Europe.
A U.S. launch of the fibrinogen product is planned, pending FDA approval.
For investors tracking Grifols (BME:GRF), the latest update combines financial progress with product news. The shares most recently traded at €10.63, with a 1% gain over the past year and a 45.4% decline over five years, highlighting how sentiment has shifted...